COVID-19, Inequality and Older People: Developing Community-Centred Interventions
AuthorsPhillipson, Christopher; orcid: 0000-0001-6220-2722; email: firstname.lastname@example.org
Yarker, Sophie; email: email@example.com
Lang, Luciana; email: firstname.lastname@example.org
Doran, Patty; orcid: 0000-0001-5930-5771; email: email@example.com
Goff, Mhorag; orcid: 0000-0003-4936-2881; email: firstname.lastname@example.org
Buffel, Tine; email: email@example.com
MetadataShow full item record
AbstractThis paper considers the basis for a ‘community-centred’ response to COVID-19. It highlights the pressures on communities weakened by austerity, growing inequalities, and cuts to social infrastructure. This paper examines the disproportionate impact of the pandemic on low-income communities, whilst highlighting the extent to which they have been excluded from debates about policies to limit the spread of COVID-19. This paper examines four approaches to assist the inclusion of neighbourhoods in strategies to tackle the pandemic: promoting community participation; recruiting advocates for those who are isolated; creating a national initiative for supporting community-centred activity; and developing policies for the long-term. This paper concludes with questions which society and communities will need to address given the potential continuation of measures to promote physical distancing.
CitationInternational Journal of Environmental Research and Public Health, volume 18, issue 15, page e8064
DescriptionFrom MDPI via Jisc Publications Router
History: accepted 2021-07-27, pub-electronic 2021-07-29
Publication status: Published
Funder: Leverhulme Trust; Grant(s): RL-2019-011
Showing items related by title, author, creator and subject.
Halogens in Eclogite Facies Minerals from the Western Gneiss Region, NorwayHughes; orcid: 0000-0002-4363-8675; email: firstname.lastname@example.org; Cuthbert; orcid: 0000-0002-1029-6357; email: email@example.com; Quas-Cohen; email: firstname.lastname@example.org; Ruzié-Hamilton; orcid: 0000-0002-2802-8123; email: email@example.com; Pawley; orcid: 0000-0002-3022-3235; email: firstname.lastname@example.org; Droop; email: email@example.com; Lyon; email: Ian.Lyon@manchester.ac.uk; Tartèse; email: firstname.lastname@example.org; Burgess; orcid: 0000-0001-7674-8718; email: email@example.com (MDPI, 2021-07-14)Ultra-high-pressure (UHP) eclogites and ultramafites and associated fluid inclusions from the Western Gneiss Region, Norwegian Caledonides, have been analysed for F, Cl, Br and I using electron-probe micro-analysis, time-of-flight secondary ion mass spectrometry and neutron-irradiated noble gas mass spectrometry. Textures of multi-phase and fluid inclusions in the cores of silicate grains indicate formation during growth of the host crystal at UHP. Halogens are predominantly hosted by fluid inclusions with a minor component from mineral inclusions such as biotite, phengite, amphibole and apatite. The reconstructed fluid composition contains between 11.3 and 12.1 wt% Cl, 870 and 8900 ppm Br and 6 and 169 ppm I. F/Cl ratios indicate efficient fractionation of F from Cl by hydrous mineral crystallisation. Heavy halogen ratios are higher than modern seawater by up to two orders of magnitude for Br/Cl and up to three orders of magnitude for I/Cl. No correlation exists between Cl and Br or I, while Br and I show good correlation, suggesting that Cl behaved differently to Br and I during subduction. Evolution to higher Br/Cl ratios is similar to trends defined by eclogitic hydration reactions and seawater evaporation, indicating preferential removal of Cl from the fluid during UHP metamorphism. This study, by analogy, offers a field model for an alternative source (continental crust) and mechanism (metasomatism by partial melts or supercritical fluids) by which halogens may be transferred to and stored in the sub-continental lithospheric mantle during transient subduction of a continental margin.
Is the Morphological Subtype of Extra-Pulmonary Neuroendocrine Carcinoma Clinically Relevant?Frizziero, Melissa; email: firstname.lastname@example.org; Durand, Alice; orcid: 0000-0002-0193-9058; email: email@example.com; Taboada, Rodrigo G.; orcid: 0000-0001-5674-2669; email: firstname.lastname@example.org; Zaninotto, Elisa; email: email@example.com; Luchini, Claudio; orcid: 0000-0003-4901-4908; email: firstname.lastname@example.org; Chakrabarty, Bipasha; email: email@example.com; Hervieu, Valérie; email: firstname.lastname@example.org; Claro, Laura C. L.; email: email@example.com; Zhou, Cong; orcid: 0000-0002-6938-4685; email: firstname.lastname@example.org; Cingarlini, Sara; email: email@example.com; et al. (MDPI, 2021-08-18)Extra-pulmonary neuroendocrine carcinomas (EP-NECs) are lethal cancers with limited treatment options. Identification of contributing factors to the observed heterogeneity of clinical outcomes within the EP-NEC family is warranted, to enable identification of effective treatments. A multicentre retrospective study investigated potential differences in “real-world” treatment/survival outcomes between small-cell (SC) versus (vs.) non-SC EP-NECs. One-hundred and seventy patients were included: 77 (45.3%) had SC EP-NECs and 93 (54.7%) had non-SC EP-NECs. Compared to the SC subgroup, the non-SC subgroup had the following features: (1) a lower mean Ki-67 index (69.3% vs. 78.7%; p = 0.002); (2) a lower proportion of cases with a Ki-67 index of ≥55% (73.9% vs. 88.7%; p = 0.025); (3) reduced sensitivity to first-line platinum/etoposide (objective response rate: 31.6% vs. 55.1%, p = 0.015; and disease control rate; 59.7% vs. 79.6%, p = 0.027); (4) worse progression-free survival (PFS) (adjusted-HR = 1.615, p = 0.016) and overall survival (OS) (adjusted-HR = 1.640, p = 0.015) in the advanced setting. Within the advanced EP-NEC cohort, subgroups according to morphological subtype and Ki-67 index (55% vs. ≥55%) had significantly different PFS (adjusted-p = 0.021) and OS (adjusted-p = 0.051), with the non-SC subgroup with a Ki-67 index of 55% and non-SC subgroup with a Ki-67 index of ≥55% showing the best and worst outcomes, respectively. To conclude, the morphological subtype of EP-NEC provides complementary information to the Ki-67 index and may aid identification of patients who could benefit from alternative first-line treatment strategies to platinum/etoposide.
Discovery and Evaluation of Protein Biomarkers as a Signature of Wellness in Late-Stage Cancer Patients in Early Phase Clinical TrialsGeary, Bethany; orcid: 0000-0002-5592-5532; email: firstname.lastname@example.org; Peat, Erin; email: email@example.com; Dransfield, Sarah; email: firstname.lastname@example.org; Cook, Natalie; orcid: 0000-0003-2606-1082; email: email@example.com; Thistlethwaite, Fiona; orcid: 0000-0002-4832-7008; email: firstname.lastname@example.org; Graham, Donna; email: email@example.com; Carter, Louise; email: firstname.lastname@example.org; Hughes, Andrew; email: Andrew.email@example.com; Krebs, Matthew G.; email: firstname.lastname@example.org; Whetton, Anthony D.; orcid: 0000-0002-1098-3878; email: email@example.com (MDPI, 2021-05-18)TARGET (tumour characterisation to guide experimental targeted therapy) is a cancer precision medicine programme focused on molecular characterisation of patients entering early phase clinical trials. Performance status (PS) measures a patient’s ability to perform a variety of activities. However, the quality of present algorithms to assess PS is limited and based on qualitative clinician assessment. Plasma samples from patients enrolled into TARGET were analysed using the mass spectrometry (MS) technique: sequential window acquisition of all theoretical fragment ion spectra (SWATH)-MS. SWATH-MS was used on a discovery cohort of 55 patients to differentiate patients into either a good or poor prognosis by creation of a Wellness Score (WS) that showed stronger prediction of overall survival (p = 0.000551) compared to PS (p = 0.001). WS was then tested against a validation cohort of 77 patients showing significant (p = 0.000451) prediction of overall survival. WS in both sets had receiver operating characteristic curve area under the curve (AUC) values of 0.76 (p = 0.002) and 0.67 (p = 0.011): AUC of PS was 0.70 (p = 0.117) and 0.55 (p = 0.548). These signatures can now be evaluated further in larger patient populations to assess their utility in a clinical setting.